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Outcome Following Loss of Primary Patency After Endovascular In-
tervention of Superficial Femoral and Popliteal Arteries
Maciej L Dryjski1,2, Monica O’Brien-Irr2, Hasan Dosluoglu1, Linda Har-
ris1,2. 1University at Buffalo, Buffalo, NY; 2Kaleida Health, Buffalo, NY
Objective: To evaluate outcomes following loss of primary patency
(LPP) in superficial femoral (SFA) and popliteal (Pop) arteries treated by
endovascular intervention (EVI)
Methods: The medical records of all SFA/Pop EVI performed by 2
Vascular Surgeons between 2005- 2008 were reviewed to identify LPP
defined as occlusion or need for re-intervention documented by duplex or
angiography. TASC II, EVI type, Rutherford Score (RS) and Rutherford
Improvement Scores (RIS) were recorded. Analysis was completed with
SPSS 15.
Results: LPP occurred in 38 patients (31%) at 8.6  5.4 months.
Twenty-four (63%) of these patients had EVI for critical limb ischemia
(Rutherford Class 4-6). Mean follow up (FU) was 20 11 months. Neither
TASC II, RS at primary EVI (PEVI) or EVI type had significant impact on
RIS at LPP. RIS at LPPwas worse than before PEVI in 55%. Re-intervention
was performed in 79% of LLP patients. Patients who never showed signifi-
cant improvement between PEVI and LPP were unlikely to improve at FU
(Table I) despite a trend to undergo multiple re-interventions (55% vs. 13%;
p0.06). Survival and limb salvage at 24 months were 75% and 92%.
Healing occurred in 46% of tissue loss patients at 11.9  11.6 months.
Conclusion: EVI of the SFA/Pop arteries are not benign procedures.
LPP occurred in nearly 1/3 of patients and 55% of those patients became
worse than prior to PEVI. Despite reasonable limb salvage, healing occurred
in only 46% and was delayed. Aggressive re-intervention after PLL may not
improve outcome in patients who did not demonstrate significant interval
improvement after PEVI.
Table 1
Classification:PEVI/LPP
interval
Improved RIS @ FU
entire group N(%)
Improved RIS@ FU
re-intervenedN(%)
Improvement¡
Worsening
19(82%) 15(88%)
Unchanged/ Worsening 3(20%) 2(15%)
P Value (Significance) 0.013 0.007
Author Disclosures: M.L. Dryjski, None; M. O’Brien-Irr, None; H.
Dosluoglu, None; L. Harris, None.
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Contemporary Results with Endovascular Therapy for Acute Limb
Ischemia
Ramyar Gilani, Mohsen Bannazadeh, James F Bena, Timur P Sarac, Vikram
S Kashyap. The Cleveland Clinic Foundation, Cleveland, OH
Objective: Endovascular therapies play an increasing role in the treat-
ment of acute limb ischemia. The purpose of this study was to assess
outcomes in patients treated for acute limb ischemia (ALI) with intra-arterial
thrombolysis and/or percutaneous mechanical thrombectomy (PMT).
Methods:Consecutive patients (n 76) with ALI of the lower extrem-
ities treated via intra-arterial methods between January 1, 2005 and Decem-
ber 31, 2006 were identified and reviewed. Overall estimates of patency,
limb salvage, and survival at 1 and 2 years were made using Kaplan-Meier
estimation. Hazard ratios from Cox proportional hazards models were used
to estimate differences in risk between groups for patency and survival.
Results: Patients with ALI (82 limbs) presenting with native artery or
graft thrombosis (76%) underwent thrombolysis and PMT (46%) under
local anesthesia (96%) for an average of 1.6 days. Adjunctive procedures were
required in 94% of patients to treat the culprit lesion with solely open
revascularization in 16%. One patient had a major bleeding episode, but
there was no intracranial hemorrhage in this cohort. 30-day amputation and
mortality rates were 14% and 6%. Primary patency at 1 and 2 years were
52.1% (95% CI, 39.3- 64.8), and 41.6% (95% CI, 27.9-55.4), while second-
ary patency rates at 1 and 2 years were 74.6% (95% CI, 63.7-85.5), and
67.5% (95% CI, 55.1-80.0) respectively (median follow up22.5 months).
Limb salvage at 1 and 2 years was 86.5% (95% CI, 77.7-95.3) and 81.9%
(95% CI, 71.5-92.3). Patients on dialysis (HR, 3.82; 95% CI, 2.22-6.59;
P0.001) and elevated creatinine levels (HR 1.16; 95% CI, 1.05- 1.29;
P0.004) were associated with primary patency loss. Overall survival at 1
and 2 years was 83.4% (95%CI, 74.4- 92.4) and 81.6% (95%CI, 72.1-91.1).
Women were at an increased risk for mortality (HR, 16.93; 95% CI,
2.18-131.58; P0.007) while those with COPD (HR, 3.12; 95% CI,
0.93-0.45; P0.065) trended towards increased risk.Conclusions: ALI remains a challenging clinical entity. Endovascular
therapy is a safe and durable treatment option for patients presenting with
lower extremity ALI. Patients with impaired renal function are associated
with worse long term patency outcomes. Female patients are associated with
decreased overall survival.
Author Disclosures: R. Gilani, None; M. Bannazadeh, None; J.F. Bena,
None; T.P. Sarac, None; V.S. Kashyap, None.
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Nilseh H Patel1, Stanley Kim1. 1Central DuPageHospital, Winfield, IL; 2St.
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Objectives: Many investigators including Transatlantic Inter-Society
Consensus (TASC) recommend against primary endovascular treatment for
severe (TASC C and D) superficial femoral artery (SFA) disease. Vein bypass
is preferable, but may not be appropriate due to comorbidities or lack of
suitable vein. This study reviews our results with Viabahn stent graft-assisted
subintimal recanalization (VASIR) for TASC C and D SFA atherosclerosis.
Methods:Thirteenmales and fourteen females, mean age 7311 years
underwent 28 VASIR for severe (TASC C 8/28, TASC D 20/28; 4/28 no
continuous infrapopliteal run-off artery) SFA disease. Indications were clau-
dication (14/28 limbs), ischemic rest pain (6/28), and tissue loss (8/28).
VASIR was chosen instead of bypass due to comorbidities or lack of vein.
Patients received aspirin and, if not already taking warfarin, they also received
clopidogrel. Patients were examined with ABI and duplex scan at 1 month,
then every 3 months after VASIR.
Results VASIR was technically successful in all. ABI averaged .47.17
pre-procedure, .89.20 post-procedure, and increased by .15 or more in
every case.Median follow-up is 20months. There were 3 perioperative (30
days) and 7 later failures including revision prior to any thrombosis. One
patient required amputation. Four have died, two with patent grafts, none
from causes related to VASIR, all more than 30 days post-VASIR. Estimated
one year primary and secondary patency were 7011% and 7310%. Failure
was not significantly associated with indications, comorbidities, or runoff
status. There was a clear distinction between patients with early failure and
the rest of the patients. None of 8 patients with failure in the first 8 months
after surgery has a patent graft. However, of 17 grafts primarily patent at 8
months, only two have failed (one thrombosed, one required preemptive
balloon angioplasty). Furthermore, although warfarin was not prescribed as
part of the protocol, no patient taking warfarin before and who resumed
warfarin after VASIR (n4) suffered failure.
Conclusions: Despite significant early failures, we found VASIR to be
durable in those who did not suffer early failure. VASIR is an acceptable
alternative to vein bypass in selected patients with severe SFA disease.
Warfarin may be valuable to reduce the risk of failure after VASIR.
Author Disclosures: J.R. Schneider, None; M.J. Verta, None; M.J.
Alonzo, None; D. Hahn, None; N.H. Patel, None; S. Kim, None.
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Major Limb Amputations Have Decreased in New York State During
the Last Decade
Roman Nowygrod1, Natalia N Egorova2, Stephanie Guillerme2, Nicholas
Morrissey1, Annetine CGelijns2, James FMcKinsey3. 1Columbia University
Medical Center, New York, NY; 2Mount Sinai School of Medicine, New
York, NY; 3Columbia University Medical Center, New York, NY
Background:Over the past decade, dramatic shifts in the management
of vascular disease have increased safety and reduced mortality. This study
examines the impact of these changes on limb salvage success.
Methods:NY State in-patient hospital discharge data from 1998-2007
were queried for patients who underwent either open or endovascular
(endo) lower extremity revascularization procedures (LER) or amputation-
s.Patients were selected by cross referencing ICD9 diagnostic and proce-
dural codes. Proportions were analyzed by chi-squared analysis, continuous
variables by t test and trends by the Cochran-Armitage test.
Results: Over time the combined rate of LE surgery decreased by 13%,
with major shifts occurring in the type of surgery. While the per capita
(100,000 population, age40) volume for endo LER doubled (34.6 to
71.7), the number of major amputations and open LER declined by 38%
(44.5 to 30.3) and 40% (104.2 to 62.2), respectively. Interventions for
patients with critical ischemia (CI) declined by 17% (88.1 to 73.5), but those
for claudication increased by 61% (17.7 to 28.6). Endo LER interventions
for both claudication and CI nearly tripled (286%, 271%). Though the total
